Integra Celebrates New Hampshire Operations Expansion
The company’s production centre on Wentworth Drive in Hudson has gained an additional 16,000 ft2, increasing both manufacturing and storage capacities. With this development, Integra is set to triple its production each year. The company, which has been in Hudson for over 10 years, aims to give back to the community, and will be recruiting a further 100 new employees which quadruples its workforce in the area in 18 months. Each facility will also meet 50% of its energy demands with the installation of solar panels, designed to provide enough electricity to power 90 houses, as part of the company’s global sustainability efforts.
“At Integra, we are proud to be able to fulfi l a critical need at a very important time in history,” explained Robert Fougere, US Site Manager and Chief Financial Offi cer at Integra Biosciences. “Our customers all around the world, whether they are researching the COVID-19 virus, patient testing on the frontline or manufacturing vaccines, are having to cope with sudden and unexpected increases in their workloads. With this expansion, we can meet their demands for equipment, while playing our part in this community and the entire world.”
Integra Vice Chairman Gary Nelson cuts the ribbon at the offi cial ceremony.
Integra Biosciences, international manufacturer of laboratory equipment with technical and manufacturing centres in Switzerland and the US, offi cially celebrated the expansion of its state-of-the-art facility in Hudson, NH, with a community ribbon cutting ceremony. The newly extended facilities will expand the company’s US presence to meet the growing demand for its laboratory liquid handling products, which have proved vital to labs around the world battling the COVID-19 pandemic.
New Hampshire Governor Chris Sununu commented on the company’s commitment to the state: “Integra didn’t slow down or back away from the mission; it understood how important it was, not just for our community, but for the entire world, to stay on task and reach production targets. It continues to show ongoing commitment to the New Hampshire Department of Health and Human Services and the local community.”
More information online:
ilmt.co/PL/Vqn0 55014pr@reply-direct.com
Appointment adds to Capacity as CRO Operation
Ion channel contract research and drug discovery company Metrion Biosciences has appointed John Montana PhD, a Non-Executive Director as part of its strategy for supporting further growth.
Dr Montana brings over 30 years’ drug discovery and development experience across the pharmaceutical, biotech and contract research sectors. An Operating Partner at Forbion, a life science venture capital fi rm, his previous roles have included Corporate Vice President, Integrated Drug Discovery at Charles River Labs, as well as multiple C-suite positions such as CSO at Argenta, CEO of Amedis, Head of Chemistry at Chiroscience and various roles at GlaxoSmithKline. Dr Montana holds a BSc in Chemistry from The University of Manchester and a PhD in Medicinal Chemistry from the University of East Anglia.
Dr Keith McCullagh, Chairman of Metrion Biosciences, said: “I am pleased to welcome John Montana to Metrion Biosciences’ board of directors. John brings substantial experience of building effective scientifi c CRO operations as well as a successful track record in drug discovery. He will be an asset to Metrion’s Board and contribute signifi cantly to the Company’s further growth and international development.”
Dr John Montana commented: “I am delighted to be joining Metrion at such an exciting time for the Company. Metrion has established itself as a leader in the ion channel contract research and drug discovery space and I look forward to joining the team and the Board on this journey, working together to extend Metrion’s capabilities.”
John Montana Keith McCullagh
54789pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
